|
US2021121406A1
|
|
Dry powder formulations of thymic stromal lymphopoietin (tslp)-binding antibodies and methods of use thereof
|
|
WO2021009692A1
|
|
Tripartite systems for protein dimerization and methods of use
|
|
WO2021001374A1
|
|
Pharmaceutical compositions for glucagon and glp-1 co-agonist peptides
|
|
WO2020234384A1
|
|
Cyclodextrin based injectable coformulations of sglt2 inhibitors and incretin peptides
|
|
US2021009671A1
|
|
Compounds and methods for treating pain
|
|
WO2020225552A1
|
|
Combination of monalizumab, durvalumab, chemotherapy and bevacizumab or cetuximab for the treatment of colorectal cancer
|
|
US2020347120A1
|
|
Dosage regimens for and compositions including anti-rsv antibodies
|
|
US2020306243A1
|
|
Compounds and conjugates thereof
|
|
WO2020187721A1
|
|
Azetidobenzodiazepine dimers and conjugates comprising them for use in the treatment of cancer
|
|
GB202000121D0
|
|
Compounds and conjugates
|
|
CA3115136A1
|
|
Pyrrolobenzodiazepine conjugates
|
|
CA3112977A1
|
|
Pyrrolobenzodiazepine conjugates
|
|
EP3806960A1
|
|
Methods of quantifying lif and uses thereof
|
|
EP3806899A2
|
|
Combination of lif inhibitors and platinum-based antineoplastic agents for use in treating cancer
|
|
SG11202012619WA
|
|
Methods for improving response to anti-lif antibody treatment in individuals with cancer
|
|
GB201908126D0
|
|
Pyrrolobenzodiazepine conjugates
|
|
EP3801630A1
|
|
Pyrrolobenzodiazepine conjugates
|
|
CN112203691A
|
|
Treatment of cancer
|
|
KR20210005097A
|
|
Conjugates that target and remove aggregates
|
|
KR20210005096A
|
|
Formulation of human anti-PD-L1 antibody
|
